🧫

SIRPα modulation in mouse models of Alzheimer's disease

active
experiment Created: 2026-04-10T23:10:58 By: etl-v1-backfill Quality: 50% ✓ SciDEX ID: exp-5f00f670-82a1-480f-8e41-6401b1b09e5d
🧫 Experiment Protocol ValidationAlzheimer's diseaseSIRPαmouse models of Alzheimer's diseaseproposed
This experiment involved modulating microglial SIRPα expression in established mouse models of Alzheimer's disease to investigate its role in neurodegeneration. The researchers examined the effects of altered SIRPα expression on synaptic loss, microglial engulfment activity, and cognitive function. This comprehensive study measured multiple outcomes including synaptic integrity, microglial phagocytosis, and behavioral performance to understand how SIRPα regulates synaptic pruning in the context of neurodegeneration.
PRIMARY OUTCOME
synaptic loss, microglial engulfment, cognitive impairment
EXPECTED OUTCOMES
Loss of microglial SIRPα results in increased synaptic loss, enhanced microglial engulfment, and worsened cognitive impairment
SUCCESS CRITERIA
- Prespecified primary endpoint (synaptic loss, microglial engulfment, cognitive impairment) improves versus control with p < 0.05 or an equivalent corrected threshold used by the study. - The effect size is biologically meaningful and reproduced across technical/biological replicates or the validation subset. - Safety, data quality, and missingness remain within protocol-defined bounds so the result is interpretable rather than driven by attrition or assay failure.
PROTOCOL
1. Establish mouse models of Alzheimer's disease cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for SIRPα, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure synaptic loss, microglial engulfment, cognitive impairment together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5. Interpret results against the baseline study rationale: This experiment involved modulating microglial SIRPα expression in established mouse models of Alzheimer's disease to investigate its role in neurodegeneration. The researchers examined the effects of altered SIRPα expression on synaptic loss, microglial engul
🧫 Experiment Extras
PATHWAY
CD47-SIRPα signaling pathway, complement pathway
MARKET PRICE
$0.50
STATUS
proposed
Metadataorigin_type: v1_polymorphic_backfill
origin_typev1_polymorphic_backfill
source_tableexperiments
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.